Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Research & Development (2016 - 2025)

Historic Research & Development for Jaguar Health (JAGX) over the last 11 years, with Q3 2025 value amounting to $3.7 million.

  • Jaguar Health's Research & Development fell 952.26% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 1112.96%. This contributed to the annual value of $16.5 million for FY2024, which is 1104.54% down from last year.
  • Latest data reveals that Jaguar Health reported Research & Development of $3.7 million as of Q3 2025, which was down 952.26% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Jaguar Health's Research & Development peaked at $6.1 million during Q3 2023, and registered a low of $2.4 million during Q1 2021.
  • For the 5-year period, Jaguar Health's Research & Development averaged around $4.1 million, with its median value being $4.0 million (2024).
  • Its Research & Development has fluctuated over the past 5 years, first soared by 18792.02% in 2021, then plummeted by 3666.67% in 2022.
  • Quarter analysis of 5 years shows Jaguar Health's Research & Development stood at $5.5 million in 2021, then fell by 21.36% to $4.3 million in 2022, then decreased by 19.67% to $3.5 million in 2023, then skyrocketed by 30.93% to $4.5 million in 2024, then dropped by 19.32% to $3.7 million in 2025.
  • Its Research & Development was $3.7 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.7 million in Q1 2025.